Breaking News

OctoPlus Enters Formulation Pact

OctoPlus N.V. has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation for an undisclosed peptide compound.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

OctoPlus N.V. has signed a feasibility agreement with a top-10 biopharmaceutical company to develop a controlled release formulation for an undisclosed peptide compound. Pending a successful evaluation, the contract may result in a full process development, manufacturing and licensing agreement. Financial terms were not disclosed....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters